Janssen Pharmaceuticals (Johnson & Johnson) has entered the game, folks. The hearing loss drug discovery game, that is. a9α10 receptor modulators emerge as a novel therapeutic strategy for hearing loss. Introducing α9α10: Researchers recently identified a target that could be used to treat hearing loss and a handful of related auditory disorders -- including tinnitus -- and soon we may have another promising hearing restoration 'horse in the race'. What's happening -- May 22, 2021 update: This week, David S. Bredt -- molecular neuroscientist and Global Head Discovery Neuroscience at Johnson & Johnson -- will be presenting the recent findings at The Inner Ear Disorders Therapeutics Summit, an upcoming digital conference taking place a few days from now (May 25 - 27). His presentation is titled: Targeting the α9α10 Nicotinic Acetylcholine Receptor for Hearing Loss Link: Targeting the α9α10 Nicotinic Acetylcholine Receptor for Hearing Loss Article: Promising targets for deafness drug discovery ...the race to find a cure seems to be getting more interesting by the day -- with new and unexpected participants joining the action, sometimes out of nowhere.